|
1）Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012; 481: 295-305
|
|
|
|
2）Bellin M, Marchetto MC, Gage FH, et al. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol. 2012; 13: 713-26
|
|
|
|
|
|
3）Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007; 318: 1920-3
|
|
|
|
|
|
4）Carette JE, Pruszak J, Varadarajan M, et al. Generation of iPSCs from cultured human malignant cells. Blood. 2010; 115: 4039-42
|
|
|
|
|
|
5）Ye Z, Zhan H, Mali P, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood. 2009; 114: 5473-80
|
|
|
|
|
|
6）Kumano K, Arai S, Hosoi M, et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood. 2012; 119: 6234-42
|
|
|
|
|
|
7）Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76
|
|
|
|
|
|
8）Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-72
|
|
|
|
|
|
9）Miyoshi N, Ishii H, Nagai K, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A. 2010; 107: 40-5
|
|
|
|
|
|
10）Utikal J, Maherali N, Kulalert W, et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009; 122: 3502-10
|
|
|
|
|
|
11）Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11: 1029-35
|
|
|
|
|
|
12）Takayama N, Nishikii H, Usui J, et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood. 2008; 111: 5298-306
|
|
|
|
|
|
13）Takayama N, Nishimura S, Nakamura S, et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med. 2010; 207: 2817-30
|
|
|
|
|
|
14）OʼHare T, Zabriskie MS, Eiring AM, et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012; 12: 513-26
|
|
|
|
|
|
15）Wang X, Lin G, Martins-Taylor K, et al. Inhibition of caspase-mediated anoikis is critical for basic fibroblast growth factor-sustained culture of human pluripotent stem cells. J Biol Chem. 2009; 284: 34054-64
|
|
|
|
|
|
16）Brill LM, Xiong W, Lee KB, et al. Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell. 2009; 5: 204-13
|
|
|
|
|